Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

PLoS Medicine

Volumn 4, Issue 12, 2007, Pages 1931-1939

  Rosenthal, Ian M ^a,b   Zhang, Ming ^a   Williams, Kathy N ^a   Peloquin, Charles A ^c   Tyagi, Sandeep ^a   Vernon, Andrew A ^d   Bishai, William R ^a,b   Chaisson, Richard E ^a,b   Grosset, Jacques H ^a   Nuermberger, Eric L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; DRUG DERIVATIVE; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SUBSTITUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TREATMENT OUTCOME; TUBERCULOSIS; ANIMAL; BACTERIAL COUNT; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DISEASE MODEL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; LUNG; MICROBIOLOGY; RECURRENT DISEASE; TIME;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ISONIAZID; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; QUINOLINES; RECURRENCE; RIFAMPIN; TIME FACTORS; TUBERCULOSIS;

EID: 38049038389     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040344     Document Type: Article

References (33)

1. Stop TB Partnership and World Health Organization (2006) Global Plan to Stop TB 2006-2015. Geneva: World Health Organization (WHO/HTM/STB/2006.35). Available: http://www.who.int/tb/publications/2006/en. Accessed 1 November 2007.
2. O'Brien RJ, Nunn PP (2001) The need for new drugs against tuberculosis. Obstacles, opportunities and next steps. Am J Respir Crit Care Med 163: 1055-1058.
3. Spigelman M, Gillespie S (2006) Tuberculosis drug development pipeline: progress and hope. Lancet 367: 945-947.
4. Andries K, Verhasselt P, Guillemont J, Gohlman H, Neefs J, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
5. Glickman SW, Rasiel EB, Hamilton CD, Kubataev A, Schulman KA (2006) A portfolio model of drug development for tuberculosis. Science 311: 1246-1247.
6. Burman W, Gallicano K, Peloquin C (2001) Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 40: 327-341.
7. Chang KC, Leung CC, Yew WW, Chan SL, Tam CL (2006) Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 174: 1153-1158.
8. Grosset J, Leventis S (1983) Adverse effects of rifampin. Rev Infect Dis 5: S440-S446.
9. Poole G, Stradling P, Worlledge S (1971) Potentially serious side effects of high-dose twice-weekly rifampin. BMJ 3: 343-347.
10. Singapore Tuberculosis Service/British Medical Research Council (1975) Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. Lancet 2: 1105-1109.
11. Anonymous (1998) Rifapentine (Priftin) data on file. Kansas City, Missouri: Hoechst Marion Roussel.
12. Tuberculosis Trials Consortium (2002) Rifapentine and isoniazid once a week versus rifampin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 360: 528-534.
13. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America (2003) Treatment of tuberculosis. Am J Respir Crit Care Med 167: 603-662.
14. Tam C, Chan S, Lam C, Leung C, Kam K, et al. (1998) Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial Report. Am J Respir Crit Care Med 157: 1726-1733.
15. Weiner M, Bock N, Peloquin C, Burman WJ, Khan A, et al. (2004) Pharmacokinetics of rifapentine at 600, 900, and 1200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 169: 1191-1197.
16. Mitchison DA (1998) Development of rifapentine: the way ahead. Int J Tuberc Lung Dis 2: 612-615.
17. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, et al. (2003) Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agent Chemother 47: 2118-2124.
18. Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, et al. (2006) Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 174: 94-101.
19. Bock N, Sterling T, Hamilton C, Pachucki C, Wang Y, et al. (2002) A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med 165: 1526-1530.
20. Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, et al. (2006) Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 173: 922-926.
21. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien, Vernon A, et al. (2004) Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169: 421-426.
22. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, et al. (2004) Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170: 1131-1134.
23. Grosset J, Ji B (1998) Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA editors. Mycobacteria II chemotherapy. New York: Chapman & Hall. pp. 51-97.
24. Rosenthal I, Williams K, Tyagi S, Vernon A, Peloquin C, et al. (2005) Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. Am J Respir Crit Care Med 172: 1457-1462.
25. Heifets L, Lindholm-Levy P, Flory M (1990) Bacterial activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 141: 626-630.
26. Nardell EA, Rubin EJ (2005) Once upon a time. . .improved intermittent therapy for tuberculosis-fact or fable? Am J Respir Crit Car Med 172: 1361-1362.
27. Chang K, Leung C, Yew W, Ho S, Tam C (2004) A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 170: 1124-1130.
28. Li J, Munsiff S, Driver C, Sackoff J (1997) Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997. Clin Infect Dis 41: 83-91.
29. Vernon AA, Iademarco MF (2004) In the treatment of tuberculosis, you get what you pay for. . .. Am J Respir Crit Care Med 170: 1040-1042.
30. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, et al. (2006) Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174: 331-338.
31. Codecasa LR, Ferrara G, Ferrarese M, Morandi MA (2006) Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir Med 100: 1566-1572.
32. Iannini PB, Kubin R, Reiter C, Tillotson G (2001) Reassuring safety profile of moxifloxacin. Clin Infect Dis 32: 1112-1114.
33. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, et al. (2003) Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis; preliminary results. J Chemother 15: 66-70.